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larization appears to afford a long-term survival benefit
in selected patients with low ejection fraction.2-4
However, the selection of patients with low ejection
fraction for revascularization remains controversial
because of the high surgical risk.5
In some patients with impaired left ventricular func-
tion, myocardial dysfunction results from infarction with
attendant necrosis and scar formation. However, in many
patients such myocardial dysfunction may be reversible
with revascularization,6-11 otherwise referred to as hiber-
nating and/or stunned myocardium.12-14 This has impor-
tant implications for patients with low ejection fraction,
in whom severe heart failure may be attributed to severe,
widespread hibernation (or stunning or both) rather than
to necrosis of a critical mass of myocardium.15 Previous
studies have shown that identification of potentially
reversible myocardial dysfunction in these patients
P atients with coronary artery disease and severe leftventricular dysfunction have a poor prognosis when
treated with medical therapy alone.1 Surgical revascu-
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appears effective for identifying those who will benefit
most from revascularization.16-21 Although these studies
suggest that myocardial viability assessment may be
beneficial for predicting short-term outcome, the long-
term prognostic benefit of such an approach remains to
be defined. Further, the relation between the severity of
anginal symptoms, the amount of ischemic myocardium,
and outcome has not been well established.
Our purpose was to evaluate the long-term benefit of
myocardial viability assessment for stratifying risk and
selecting patients with low ejection fraction for coronary
artery bypass grafting (CABG) and to determine the
relation between the severity of anginal symptoms, the
amount of ischemic myocardium, and clinical outcome.
Methods
Patient population and data collection. All patients who
were undergoing myocardial viability assessment from
February 1989 through November 1991 for any symptom of
coronary artery disease, who had moderate-to-severe left ven-
tricular dysfunction (ejection fraction, <40%), and who were
potential candidates for myocardial revascularization were
selected for this study. Patients were referred by University of
California, Los Angeles faculty and by physicians from the
Los Angeles area, the majority of whom were cardiologists or
cardiothoracic surgeons.
All patients underwent coronary angiography by standard
techniques. The criterion for evaluating the angiographic
extent of coronary artery disease was either a 70% or more
stenosis in the proximal left anterior descending, circumflex,
or right coronary artery or their major branches, or 50% or
more stenosis of the left main coronary artery. The left ven-
tricular ejection fraction was calculated from biplane contrast
left ventriculography in 70 patients and 2-dimensional echo-
cardiography in 23 patients. The results are summarized in
Table I.
Evaluation of myocardial viability. Myocardial viability
was evaluated with positron-emission tomography (PET)
with 13N-ammonia (20 mCi) as a tracer of blood flow and
18F-deoxyglucose (FDG; 10 mCi) as an indicator of glucose
use. Imaging was performed on a whole body PET tomo-
graph (model 931-108; Siemens-Computer Technology, Inc,
Knoxville, Tenn). Studies were acquired in the glucose-
loaded state, after oral administration of 50 g of glucose.
The analysis of PET images was previously described in
detail.16 Briefly, analysis of regional myocardial perfusion,
glucose uptake, and their relationship was performed with a
20-segment model. Visual analysis was as follows: Corres-
ponding 13N-ammonia and FDG images were scored semi-
quantitatively in all 20 segments by consensus visual analysis
of 2 observers who were blinded to the rest of the patient’s
data. Segments with a perfusion defect were classified as a
match, when both 13N-ammonia and FDG uptake were con-
cordantly reduced, or a mismatch when segmental FDG
uptake was increased relative to perfusion. The total myocar-
dial extent of PET patterns was determined by dividing the
number of segments that showed a match or mismatch pattern
by 20 (ie, total number of left ventricular segments).
Quantitative analysis was as follows: Regional 13N-ammonia
and FDG uptake were also evaluated quantitatively with vol-
ume-weighted polar maps, as described previously.16 Seg-
ments classified as a PET match on visual analysis had on
average a concordant reduction in 13N-ammonia and FDG
uptake on quantitative analysis (mean ± SD, 56% ± 19% ver-
sus 57% ± 18%, respectively; P = .712). Conversely, myocar-
dial segments classified as a PET mismatch by visual analysis
had, on average, a significant relative increase (to perfusion)
in FDG uptake on quantitative analysis (mean ± SD, 57% ±
15% versus 93% ± 20%, respectively; P < .001).
Follow-up. The decision to treat a patient with revascular-
ization or medical therapy was made by the primary physi-
cians and the patients on the basis of clinical grounds.
Because of refractory symptoms, 5 patients who initially re-
ceived medical therapy underwent late revascularization (>6
months after the PET study), and 2 patients received a heart
transplant. These patients were censored from further analy-
sis at the time of revascularization or heart transplantation.
Patients were followed for a median of 3.8 years (range, 0 to
6.2 years). Information on the vital status of patients was
obtained by telephone contact with the patient, relatives, and
referring physicians and from review of hospital records and
death certificates by an investigator who was blinded to the
rest of the data. The cause of death was determined from
death certificates, hospital records, or autopsy reports. Deaths
caused by acute myocardial infarction, ventricular arrhyth-
mia, and congestive heart failure were considered cardiac
deaths. Death was considered sudden when it was unexpected
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Table I. Baseline characteristics of study patients
Medical 
therapy Revascularization 
Variable (n = 50) (n = 43) P value
Age (yr)* 69 (60.3, 73.6) 68 (61.2, 73.5) .78
Male sex (No.; %) 40 (80) 38 (88) .27
Angina class III-IV† 15 (30) 19 (44) .16
(No.; %)
Diabetes (No.; %) 5 (10) 7 (16) .37
Hypertension (No.; %) 6 (12) 11 (26) .06
Prior MI (No.; %) 32 (64) 31 (72) .41
CHF class III-IV‡ 31 (62) 32 (74) .50
(No.; %)
LV ejection fraction* 0.25 (0.2, 0.3) 0.25 (0.2, 0.3) .61
One vessel§ (No.; %) 9 (18) 8 (19) .94
Two vessels (No.; %) 28 (56) 16 (37) .09
Three vessels (No.; %) 12 (24) 16 (37) .18
Left main (No.; %) 1 (2) 3 (7) .33
Extent of PET mismatch* 12 (6.4, 17.6) 18 (7.5, 28.8) .20
MI, Myocardial infarction; CHF, congestive heart failure; LV, left ventricular.
*Data presented are median (lower, upper, quartiles).
†Canadian Cardiovascular Society.
‡New York Heart Association.
§Reflect proximal left anterior descending coronary artery disease.
and was witnessed to occur within 1 hour of the onset of
symptoms.
Statistical analysis. Baseline differences in important
prognostic factors between the medical and revascularization
groups were assessed with c 2 test for discrete variables and
the Wilcoxon rank sum test for continuous variables.
Analysis of the primary end point is based on an intention-to-
treat strategy. Survival curves were constructed from standard
life table calculations after adjustment for differences in
prognostic factors with the Cox proportional hazards
model.22 For construction of survival curves, patients were
assigned to the PET mismatch group when more than 5% of
the left ventricle had a perfusion-metabolic mismatch pattern,
which was found to have the best trade-off between sensitiv-
ity and specificity for predicting cardiac death by receiver
operating–characteristic analysis.16 The Cox model was used
to determine the influence of multiple factors on survival.
Treatment method (ie, revascularization or medical therapy)
was then added as a covariate in the Cox model so that sur-
vival differences between treatments could be tested. P val-
ues less than .10 also are reported because they were taken to
indicate trends toward statistical significance.
Results
Ninety-three patients met the inclusion criteria, of
whom 50 patients received medical therapy and 43
patients underwent surgical revascularization. The base-
line characteristics of the study group are summarized
in Table I. There were some imbalances between the 2
groups, none of which reached statistical significance.
The surgical group tended to have more male patients
and more patients with severe angina, advanced heart
failure, diabetes, hypertension, prior myocardial infarc-
tion, and larger areas of PET mismatch. Importantly,
there was a significant overlap between the 2 groups
with respect to important prognostic variables, includ-
ing age, extent of coronary artery disease, and degree of
left ventricular dysfunction.
Operative characteristics of patients undergoing
CABG. All 43 patients underwent complete revascu-
larization on the basis of the anatomic distribution of
coronary stenoses and a review of operative reports.
CABG was performed at many centers throughout
Southern California. Eleven patients (26%) had a his-
tory of previous CABG. Standard cardiopulmonary
bypass and moderate hypothermia (28°C) were used in
all patients. Cold blood cardioplegia was used in 40
patients (93%), and crystalloid cardioplegia was used
in 3 patients (7%). Cardioplegic solution was delivered
via the antegrade route in 17 patients (40%), whereas
combined antegrade and retrograde (coronary sinus)
delivery of cardioplegic solution was used in 26 (60%)
patients. The mean (± SD) number of grafts for the
group was 3.9 (± 1.1). Arterial grafts were used in 10
patients (23%). Thirteen patients (30%) required
intraaortic balloon pump support after the operation.
Survival analysis. Thirty-seven (40%) deaths, all of
which were cardiac in origin, occurred during the fol-
low-up period. Revascularization (P = .009) and the
extent of PET mismatch (P = .012) were the only sta-
tistically significant predictors of survival in univariate
analysis. Sex, presence of Q waves on the resting elec-
trocardiogram, diabetes, hypertension, extent of PET
match, type of cardioplegia or its route of delivery, use
of arterial conduits, and the extent of coronary artery
disease on angiography were not significant predictors
of survival in the univariate analysis. 
A stepwise Cox model analysis was performed to
determine the prognostic contribution of mismatch
when covariates with borderline significance in the uni-
variate analysis were included in the model. The vari-
ables considered in this analysis were age, angina, heart
failure class, ejection fraction, prior myocardial infarc-
tion, extent of PET mismatch, type of treatment, and
interaction between treatment and extent of PET mis-
match, treatment and heart failure class, and treatment
and prior myocardial infarction. In this model, only
prior myocardial infarction (relative risk and 95% con-
fidence interval; 1.49, 1.02 to 2.18; P = .038), heart fail-
ure class (1.59, 0.94 to 2.71; P = .086), and the extent of
PET mismatch (2.52, 1.19 to 5.32; P = .016) were sig-
nificant predictors of outcome. These variables contin-
ued to be independent predictors of outcome when
treatment method was entered into the Cox model so
that differences between CABG and medical therapy
groups could be tested. After adjusting for these impor-
tant prognostic factors, survival was significantly better
over time with revascularization than with medical ther-
apy alone (Fig 1). The estimated adjusted survival prob-
ability for the 50 patients on medical therapy was 77%,
46%, and 33% after 1, 3, and 5 years of follow-up,
respectively. In contrast, the estimated adjusted survival
probability for the 43 patients undergoing revascular-
ization was 95%, 84%, and 78% after the same time
intervals (P = .0002). The improved survival with
CABG was most apparent among patients with a left
ventricular ejection fraction 20% or more (Fig 2).
Severity of anginal symptoms, amount of viable
myocardium, and clinical outcome. To further evalu-
ate the value of myocardial viability assessment for risk
stratification of patients with left ventricular dysfunc-
tion, the study patients were subgrouped by presence or
absence of mismatch (an important prognostic factor by
multivariable analysis) on their preoperative PET
images.
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There were 25 deaths among patients receiving med-
ical therapy, of which 11 deaths occurred in the group
with PET mismatch. The mode of death was sudden in
8 of 11 (73%) patients with PET mismatch and in 4 of
14 (29%) patients without mismatch (P = .031). The
estimated 4-year adjusted survival probability of all
medically treated patients was poor, but it was signifi-
cantly lower among those with PET mismatch as com-
pared with those without such a mismatch: 30% versus
52%, respectively (P = .003; Fig 3). Interestingly, most
of the deaths in the group with PET mismatch occurred
early in the course of the follow-up period.
There were 12 deaths among patients undergoing
revascularization. Four of these deaths occurred during
the 30-day perioperative period, resulting in a perioper-
ative mortality of 9.3%. The 4 in-hospital deaths in our
study were due to low output state in 3 patients and sep-
sis with multi-organ failure in 1 patient. In these
patients, ejection fraction ranged from 11% to 25%; all
had class III or IV heart failure, and 2 patients also had
severe angina. Eleven of 43 (26%) patients in the sur-
gical group underwent repeat CABG, of whom 2
patients died within the 30-day postoperative period.
The 30-day perioperative mortality of patients under-
going repeat CABG was higher, although not statisti-
cally significant, than that of those receiving their first
operation (2 of 11 [18.2%] versus 2 of 32 [6.3%],
respectively; P = .266). The estimated 4-year adjusted
survival probability of revascularized patients with a
preoperative PET mismatch was similar to those with-
out a mismatch (75% versus 77%; P = .612). 
Among patients with PET mismatch, those undergo-
ing revascularization had a higher estimated 4-year
adjusted survival probability as compared with those
receiving medical therapy alone (75% versus 30%; P =
.007; Fig 3). This survival benefit was apparent in
patients with severe angina and in those with minimal
or no anginal symptoms (Fig 4). Among patients with-
out PET mismatch, revascularization tended to improve
survival compared with medical therapy only among
those patients with severe angina (4-year adjusted sur-
vival probability, 100% versus 60%; P = .085), where-
as no survival benefit was apparent in patients with
minimal or no anginal symptoms (4-year adjusted sur-
vival probability, 63% versus 52%; P = .462; Fig 4).
Changes in anginal and heart failure symptoms.
In the medically treated patients, there was no signifi-
cant change in the number of angina-free patients dur-
ing the follow-up period (30% versus 24%; P = .221).
In contrast, medical treatment provided some relief in
the severity of heart failure symptoms during the
course of the follow-up period (median [25th, 75th]
heart failure class from baseline to follow-up, 3 [2, 3]
to 2.5 [2, 3]; P = .053). In the surgical patients, there
was a significant increase in the number of angina-free
patients during the follow-up period (44% versus 7%;
P < .001). Likewise, revascularization provided a sig-
nificant relief in the severity of heart failure symptoms
(median [25th, 75th] heart failure class from baseline to
follow-up, 3 [2, 4] to 2 [1, 3]; P < .001). This was most
apparent in patients with PET mismatch (3 [2.75, 4] to
2 [1, 2]; P < .001). In patients without PET mismatch,
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Fig 1. Plot shows Kaplan-Meier estimated survival probabilities for patients with left ventricular ejection fraction
less than 40% treated medically and with CABG. The left panel shows the unadjusted (for baseline prognostic
factors) survival estimates, and the right panel shows the adjusted survival estimates.
revascularization tended to improve heart failure symp-
toms only when those were associated with severe
angina, (3 [2, 3] to 2 [2, 3]; P = .068), whereas no
improvement was observed among patients in whom
heart failure was associated with minimal or no angina
(3 [2.75, 3.25] to 3 [2, 3]; P = .108).
Discussion
Patients with coronary artery disease and severely
impaired cardiac function have a poor prognosis when
treated with medical therapy alone.1 In selected
patients, CABG may improve survival and symp-
toms.2-5,15 However, operative deaths are high, and
much controversy remains about the proper selection
of patients with severe left ventricular dysfunction for
revascularization, especially among those patients with
heart failure symptoms and minimal or no angina.5 The
findings of this study suggest that in patients with evi-
dence of viable myocardium, as assessed by the PET
mismatch pattern, the 4-year adjusted survival with
surgical revascularization is better compared with med-
ical therapy alone (Fig 3). In patients without such evi-
dence of viability, revascularization tended to improve
survival over medical therapy only among those
patients with severe angina, whereas no survival advan-
tage was apparent in patients with minimal or no angi-
nal symptoms (Fig 4). These results extend the obser-
vations of previous studies16-20 from our group and
others in 2 important ways: by demonstrating the long-
term benefit of the use of myocardial viability infor-
mation for stratifying risk and selecting patients with
impaired cardiac function for revascularization and by
describing the interrelation between the severity of
anginal symptoms, the presence of viable myocardium,
and clinical outcome.
In this study, the overall adjusted survival of patients
who received medical therapy alone was very poor,
consistent with previous studies of the natural history
of coronary artery disease.1-4 However, long-term sur-
vival was poorer among those patients with viable
myocardium, as assessed by the PET mismatch pattern
(Fig 3). This finding confirms and extends the results of
previous reports, demonstrating that 1-year event-free
survival in patients receiving medical therapy appears
to be better among those patients without evidence of
dysfunctional but viable myocardium, as determined
by PET, thallium, or echocardiographic criteria.16-20
Although the reason for the association between viable
myocardium and adverse outcome in medically treated
patients is not well understood, it could be explained by
the higher risk of ischemic events (ie, myocardial
ischemia, infarction, and ventricular arrhythmia) when
a severely stenosed coronary artery supplies an area of
viable rather than infarcted myocardium. Among
patients who receive medical therapy, sudden death
occurred more frequently in those patients with PET
mismatch compared with those patients without such
mismatch (73% versus 29%). In these patients, sudden
The Journal of Thoracic and
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Fig 2. Plot shows adjusted Kaplan-Meier estimated survival
probabilities by level of resting ejection fraction for patients
with moderate or severe left ventricular dysfunction treated
medically and with CABG .
death may be caused by a further reduction in blood
supply and/or increased oxygen demand in hibernating
regions that ultimately leads to reinfarction and/or
lethal arrhythmia.
In contrast, the long-term adjusted survival of patients
undergoing revascularization was better than that
observed with medical therapy. This finding is consis-
tent with reports of previous cohort and large registry
studies.2-4 Long-term survival with revascularization
was similar in patients with and without evidence of
PET mismatch. However, the survival benefit from
revascularization over medical therapy was statistically
significant only among patients with PET mismatch. In
this subgroup of patients, the benefit of revasculariza-
tion persisted for 5 years of follow-up and actually
increased in magnitude throughout this period, corrobo-
rating initial observations from our group and others
(Fig 3).16-19 The operative mortality rate in our study
was higher than that reported in some series of patients
with low ejection fraction (<35%).2,3 In these reports,
the proportion of patients with class III or IV heart fail-
ure was also low (<5%). In our study, however, 74% of
the surgical patients had low ejection fraction and severe
heart failure (Table I). Other reports in patients with low
ejection fraction and class III or IV heart failure have
found that operative mortality rates range from 5.9% to
14.9%,23 consistent with that observed in this study.
Finally, patients in this study underwent CABG at many
centers throughout Southern California with (likely) dif-
ferent levels of expertise in the management of high-risk
revascularization. Therefore the operative mortality in
our study probably reflects the mortality rate in unse-
lected rather than in highly experienced centers.
Importantly, the survival benefit from revasculariza-
tion in patients with PET mismatch appeared to be
independent of symptoms and was actually greatest
among those patients with minimal or no angina. In
these patients, CABG improved both anginal and heart
failure symptoms. In contrast, in patients without a
PET mismatch, CABG appears to improve survival
and symptoms only among those patients with limiting
angina (Fig 4). Patients with no evidence of viability
by PET and minimal or no angina had a lower and
similar long-term outcome with revascularization or
medical therapy. These findings provide new and
important information concerning the value of viabili-
ty assessment for predicting outcome in patients with
severe left ventricular dysfunction, in particular
among those patients who have minimal or no angina.
Indeed, previous studies found that patients with heart
failure and no ischemic symptoms had the same out-
come with surgical revascularization as with medical
therapy and concluded that these patients should not
undergo an operation.2 In these studies, however, func-
tional tests of ischemia were not available. Symptoms
of cardiac dysfunction, such as dyspnea and heart fail-
ure or their hemodynamic correlates, may be the pri-
mary clinical manifestation of ischemic myocardium
in patients with severely depressed left ventricular
function. Our results suggest that patients with
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Fig 3. Plot shows adjusted Kaplan-Meier estimated survival probabilities for patients with left ventricular dys-
function treated medically and with CABG by presence or absence of PET mismatch, reflecting hibernating
myocardium.
ischemic cardiomyopathy who have minimal or no
angina can benefit from revascularization if relatively
large areas of viable myocardium can be identified
before the operation. In these patients, long-term sur-
vival with CABG appears to be comparable to that
achieved with heart transplantation.24
Our findings are also important in that they define the
subgroup of patients with ischemic cardiomyopathy in
whom viability assessment may be critically important
for management decisions (Fig 4). Our findings suggest
that viability assessment was relatively less important in
patients with poor ejection fraction and severe angina,
because they appeared to benefit from revascularization
regardless of viability information, presumably by
improving ventricular function and/or preventing fur-
ther loss of functioning myocytes. This is in keeping
with the extensive surgical literature.5 In contrast, our
findings suggest that viability assessment was most
beneficial among patients with poor ejection fraction
and minimal or no anginal symptoms at presentation.
Indeed, long-term outcome with revascularization was
better only among patients with evidence of viable
myocardium by PET, whereas no difference in survival
was observed among those without viable myocardium. 
Limitations of the study
This study was not a randomized controlled trial, and
the possibility of treatment selection bias exists, even
after controlling for important prognostic variables.
However, in the absence of randomized studies that
compare the outcomes of medical therapy and CABG
in patients with low ejection fraction on the basis of the
presence or absence of viable myocardium, observa-
tional studies such as this are the main source of insight
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Fig 4. Plot shows adjusted Kaplan-Meier estimated survival probabilities for patients with left ventricular dysfunction
treated medically and with CABG by presence or absence of PET mismatch and by severity of anginal symptoms.
concerning these patients. Moreover, it is important to
note that multiple observational studies, which use dif-
ferent methods for evaluating myocardial viability, all
suggest that short-term outcome in patients with
depressed left ventricular function but evidence of via-
bility is better with revascularization than with medical
therapy alone.16-20 The concurrence of these studies
provides more support for this conclusion than the re-
sults of any 1 study.
Conclusions
The present study shows that patients with severe left
ventricular dysfunction and evidence of relatively large
areas of viable myocardium, as assessed by PET, have
improved long-term survival with revascularization as
compared with medical therapy. This survival benefit is
associated with a significant improvement in angina
and heart failure symptoms. Long-term surgical sur-
vival benefit and symptomatic improvement in patients
without evidence of viability is apparent only among
those those with severe angina. These results suggest
that viability assessment is important for selecting
patients with low ejection fraction who will benefit
most from revascularization, in particular if minimal or
no anginal symptoms are present.
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